DexCom, Inc. (DXCM): Business Model Canvas [June-2026 Updated]

This ready-made Business Model Canvas for DexCom, Inc. gives you a practical, research-based view of how the Company creates, delivers, and captures value through the G7 15-Day CGM platform, the Stelo biosensor, and a user base of 3.5 million active users, backed by $2.4 billion in cash and expanded manufacturing capacity. You'll see its main growth drivers, including CGM R&D, software development, global expansion, and partnerships such as ŌURA app integration, Tandem Mobi compatibility, Signos distribution, and RAMQ reimbursement in Québec, along with the key customer segments, channels, revenue streams, and cost pressures that shape the business.

DexCom, Inc. - Canvas Business Model: Key Partnerships

DexCom, Inc. depends on partnerships that connect its continuous glucose monitoring data to devices, software, insurers, and reimbursement systems. These relationships matter because they extend distribution, raise product utility, and improve patient access without DexCom having to build every channel itself.

Partnership area	Business role	Why it matters
ŌURA app integration	Consumer and metabolic health data integration	Expands DexCom data use beyond glucose reading into sleep, activity, and wellness workflows
Tandem Mobi pump compatibility	Connected diabetes device ecosystem	Supports automated insulin delivery and increases switching costs for users
Signos distribution agreement	Digital health and weight-management channel	Broadens access to non-insulin metabolic health users and coaching-based programs
RAMQ reimbursement in Québec	Public payer access	Improves affordability and prescription adoption in a provincial reimbursement system
Partner ecosystem for metabolic health	Platform expansion	Creates a network effect around CGM data, apps, pumps, coaches, and payers

ŌURA app integration is important because it links glucose data with a consumer health platform focused on sleep, activity, and recovery. For DexCom, this partnership supports a wider use case than insulin management alone. It helps position continuous glucose monitoring as part of everyday metabolic health tracking, which is relevant for users who want to connect food, exercise, sleep, and glucose patterns in one place.

• It expands the audience beyond people already managing insulin.
• It supports user retention because data becomes more useful when it sits inside a broader health app.
• It strengthens DexCom's role as a data layer rather than only a sensor maker.

Tandem Mobi pump compatibility is a core strategic partnership because it ties DexCom CGM data to automated insulin delivery. The value here is operational, not just technical. When CGM data feeds a pump system, the user gets a tighter loop between sensing and insulin dosing, which makes the combined system harder to replace.

• It supports patient stickiness through device interoperability.
• It increases the clinical value of DexCom data in diabetes treatment.
• It helps DexCom stay embedded in physician-recommended diabetes technology stacks.

Signos distribution agreement supports DexCom's move into metabolic health beyond traditional diabetes care. Signos is built around CGM-guided coaching and behavior change, so the relationship gives DexCom exposure to users interested in weight management, nutrition, and lifestyle feedback. This matters because it opens a channel where glucose data is used for daily decision-making, not only disease management.

The partner model also helps DexCom reach consumers through a service layer. Instead of selling only to clinics, hospitals, and pharmacies, DexCom can reach users through digital programs that package CGM with coaching and tracking tools.

RAMQ reimbursement in Québec matters because reimbursement reduces out-of-pocket cost barriers. In public payer markets, coverage can influence whether a patient starts CGM and whether a prescriber prefers one device over another. For DexCom, provincial reimbursement is not just a sales issue. It is a market access issue that affects adoption speed, prescription volume, and competitive position in Canada.

Public reimbursement also changes the economics of the partnership network. When a payer covers CGM, manufacturers, distributors, pharmacies, and clinicians all operate with a lower affordability hurdle, which can support steadier demand.

Partner ecosystem for metabolic health is the broader business logic behind all of these relationships. DexCom is building a network where glucose data can move across consumer apps, insulin pumps, coaching platforms, and reimbursement channels. That makes the company more than a hardware supplier. It becomes a data platform with multiple endpoints.

Partner type	Examples	Strategic impact on DexCom
Consumer health apps	ŌURA	Raises engagement and broadens daily use cases
Insulin delivery devices	Tandem Mobi	Improves clinical utility and device lock-in
Digital coaching and distribution	Signos	Adds direct-to-consumer reach and lifestyle-health positioning
Public payers	RAMQ	Improves access and lowers patient cost barriers
Clinics and prescribers	Endocrinology and primary care networks	Drives clinical adoption and repeat prescribing

This ecosystem matters because DexCom's value increases when more partners use the same glucose data in different ways. A pump partner uses it for insulin automation. A consumer app uses it for behavior tracking. A payer uses it for access control. A coaching platform uses it for habit change.

The strategic effect is that DexCom can create multiple revenue paths from one core product category. That lowers dependence on a single channel and supports broader market penetration across diabetes care and metabolic health.

DexCom, Inc. - Canvas Business Model: Key Activities

$3.62 billion in 2023 revenue, $486.5 million in research and development expense, and $1.46 billion in selling, general, and administrative expense frame the scale of the main operating activities.

Activity area	Real-life numbers and dates	Why it matters
CGM R&D and product launches	$486.5 million R&D expense in 2023; G7 U.S. launch in 2023; Stelo FDA clearance in March 2024	Supports sensor accuracy, new form factors, and new customer segments
Manufacturing expansion	$159.8 million capital expenditures in 2023; $1.23 billion cash and cash equivalents at December 31, 2023	Supports higher sensor output, supply reliability, and unit-cost control
Software and app development	Apple Watch integration, smartphone apps, and remote-sharing features across G7 and Stelo product lines	Improves user retention, clinician use, and ecosystem stickiness
Regulatory compliance and recalls	FDA clearance for Stelo in March 2024; quality-system controls required across U.S., EU, and other markets	Determines market access and lowers product, labeling, and reporting risk
Global distribution and market expansion	2023 revenue outside the U.S. was $1.32 billion; U.S. revenue was $2.30 billion	Shows dependence on global reimbursement, distributors, and local launches

CGM R&D and product launches are the core activity because DexCom has to keep improving continuous glucose monitoring accuracy, wear time, and ease of use. In 2023, R&D expense was $486.5 million, equal to about 13.4% of revenue ($486.5 million ÷ $3.62 billion). That level of spending shows that product development is not a side task; it is the main driver of future sales. The most important launch activity was G7 in the U.S. in 2023, followed by Stelo FDA clearance in March 2024. Stelo matters because it opened a new category: adults not using insulin.

Manufacturing expansion is a required activity because CGM is a high-volume sensor business. DexCom reported $159.8 million in capital expenditures in 2023, which signals ongoing investment in production capacity, equipment, and supply chain infrastructure. The company also ended 2023 with $1.23 billion in cash and cash equivalents, which supports factory spending and working capital needs. For a CGM company, manufacturing is not only about making more units; it is about maintaining yield, lowering defects, and avoiding stock-outs when launches scale quickly.

• $159.8 million capital expenditures in 2023
• $1.23 billion cash and cash equivalents at December 31, 2023
• $3.62 billion total revenue in 2023

Software and app development is a key activity because the sensor alone does not create the full customer experience. DexCom's apps, data-sharing tools, and device integrations connect readings to phones, watches, caregivers, and clinicians. This matters because CGM value depends on real-time visibility, alerts, and usability. In practice, software supports retention: if a user's glucose data is easy to see and share, the product becomes harder to replace. It also supports clinician adoption because remote data review makes treatment decisions easier.

Financial item	2023 amount
Revenue	$3.62 billion
Cost of sales	$1.23 billion
Gross profit	$2.39 billion
Research and development	$486.5 million
Selling, general, and administrative	$1.46 billion

Regulatory compliance and recalls are unavoidable activities because CGM products are medical devices. DexCom's U.S. expansion into over-the-counter CGM required FDA clearance for Stelo in March 2024. That is a regulatory milestone, but it also means the company must maintain ongoing compliance for labeling, adverse event reporting, quality systems, and post-market monitoring. In this business, even small defects can trigger corrective action because sensors are used daily and at scale. Regulatory work therefore protects market access and revenue continuity.

Global distribution and market expansion are key activities because DexCom sells into multiple geographies with different reimbursement and regulatory rules. In 2023, U.S. revenue was $2.30 billion, while non-U.S. revenue was $1.32 billion. That split shows a broad international business but also continued reliance on the U.S. market. Global expansion requires local approvals, distributor management, reimbursement work, and launch execution by country. It also affects manufacturing planning because international demand adds complexity to forecasting and inventory allocation.

• U.S. revenue in 2023: $2.30 billion
• Non-U.S. revenue in 2023: $1.32 billion
• Total revenue in 2023: $3.62 billion
• R&D expense in 2023: $486.5 million
• Capital expenditures in 2023: $159.8 million
• Cash and cash equivalents at December 31, 2023: $1.23 billion

For academic work, the key activities section can be written around five numbers: $486.5 million R&D, $159.8 million capex, $3.62 billion revenue, $2.30 billion U.S. revenue, and $1.32 billion non-U.S. revenue.

DexCom, Inc. - Canvas Business Model: Key Resources

3.5 million active users

$2.4 billion in cash and cash equivalents

Key resource	Real-life number or amount	Business model role
G7 15-Day CGM platform	15 days	Continuous glucose monitoring platform with longer wear time
Stelo biosensor and app	14 days	Over-the-counter glucose biosensor system and app-based user interface
Active users	3.5 million	Installed user base supporting recurring sensor demand
Cash and cash equivalents	$2.4 billion	Liquidity for product development, manufacturing, and commercial expansion

• 15-day wear on the G7 platform raises the value of the installed sensor ecosystem because fewer sensor changes can improve convenience.
• 14-day wear on Stelo supports a direct-to-consumer style product model tied to app use and recurring biosensor replacements.
• 3.5 million active users show the scale of the recurring customer base behind sensor sales.
• $2.4 billion in cash gives DexCom room to fund operations without immediate financing pressure.

The G7 15-Day CGM platform is a core physical and digital asset because it combines the sensor, transmitter, software, and data flow that support recurring use. In business model terms, this resource matters because it drives repeat purchases, software engagement, and clinical adoption across insulin users and non-insulin users.

The Stelo biosensor and app add a second resource layer. The product expands DexCom's reach beyond prescription-only users and turns app software into part of the value chain. The 14-day sensor cycle is important because wear duration directly affects replacement frequency, which shapes recurring revenue potential.

The 3.5 million active users resource matters because it reflects scale. A large installed base usually lowers customer acquisition pressure per user over time and increases the value of connected data, support, and platform familiarity.

The $2.4 billion cash position is a financial resource, not a product resource. It supports research and development, sales and marketing, manufacturing build-out, and working capital needs. In plain English, cash is the money a company can use now, while cash flow is the money moving in and out of the business over time.

Expanded manufacturing capacity is a strategic resource because CGM businesses depend on reliable output, quality control, and supply continuity. If capacity rises, DexCom can meet higher demand for sensors and biosensors without the same risk of shortages or bottlenecks.

• Product resources: G7 15-Day CGM platform, Stelo biosensor, app software
• Customer resources: 3.5 million active users
• Financial resources: $2.4 billion cash and cash equivalents
• Operational resources: expanded manufacturing capacity

In a Business Model Canvas, these resources support value creation, customer retention, and scale. The combination of a longer-wear CGM platform, an app-linked biosensor, a multi-million-user base, and strong liquidity is what allows DexCom to keep developing, producing, and selling glucose monitoring products at scale.

DexCom, Inc. - Canvas Business Model: Value Propositions

DexCom, Inc. offers a longer-wear continuous glucose monitoring system, real-time glucose data every 5 minutes, and products for both insulin users and adults with non-insulin metabolic health needs. Its value proposition centers on reducing fingerstick dependence, improving day-to-day glucose visibility, and making access simpler through pharmacy and insurance workflows.

Value Proposition Area	Real-Life Number or Product Detail	Business Impact
Longer-wear CGM	15 days	Fewer sensor changes and lower interruption in monitoring
Glucose data frequency	Every 5 minutes	Continuous visibility into glucose changes across the day and night
Wear duration of earlier flagship CGM	10 days	Shows the move from shorter wear to longer wear
Non-insulin metabolic health product	18 years and older, not using insulin	Expands the addressable user base beyond insulin-treated diabetes
Prescription status for over-the-counter CGM	No prescription	Reduces access friction for eligible consumers
Clinical insulin-pump integration	1 hour warm-up for Dexcom G7	Shortens time to usable data after sensor start

Longer-wear 15-day CGM is a direct product value because it reduces how often you need to replace a sensor. A 15-day wear period means up to 24 sensor periods per year instead of 36.5 sensor periods for a 10-day sensor, before any grace periods or early replacements. That lower replacement frequency matters for convenience, adherence, and supply handling. For academic work, this is a clear example of how product design affects user retention and operating simplicity.

• 15 days of wear per sensor
• 10 days for the earlier flagship CGM wear period
• 1 hour warm-up for Dexcom G7
• 5-minute glucose readings

Real-time glucose monitoring is the core functional value. DexCom systems provide glucose readings every 5 minutes, which equals 288 readings per day. That matters because glucose can change quickly after meals, exercise, sleep, or insulin use. Real-time data can support faster action than a single daily fingerstick. For students writing about the business model, this is the clearest link between product capability and customer value: higher-frequency data increases usefulness, which can support repeat usage and system loyalty.

• 288 glucose data points per day at 5-minute intervals
• Continuous tracking across 24 hours
• Designed for users who need visibility into highs and lows

Non-insulin metabolic health tracking extends the value proposition beyond diabetes treatment. DexCom launched an over-the-counter CGM under the name Stelo for adults 18 years and older who do not use insulin. That matters because the product is not limited to prescription-only diabetes care. It targets people who want to observe how food, sleep, and exercise affect glucose patterns. From a business model angle, this opens a separate market segment with different buying behavior and a simpler access path.

• Adults 18 years and older
• No insulin use
• No prescription required

Segment	Access Model	Primary Need
Insulin users	Prescription and payer-based access	Glucose monitoring for treatment decisions
Non-insulin adults	Over-the-counter access	Behavior tracking and metabolic awareness

Simplified ordering and insurance verification lowers friction in getting started and staying on the product. For a medical device business, access is part of the value proposition, not just a back-office process. When ordering is simpler and coverage checks are faster, the user faces fewer delays between diagnosis, prescription, and first use. This is especially important in a category where adherence and continuity depend on uninterrupted supply delivery. In academic analysis, this is a useful example of how service design supports product adoption.

• Prescription-based CGM users
• Insurance verification workflow
• Pharmacy-channel access
• Lower administrative burden for users and clinics

Integrated insulin dosing support is a high-value proposition for people on intensive insulin therapy and for the clinicians managing them. DexCom CGM data can be used with insulin delivery systems and diabetes management workflows that rely on current glucose readings. The value is not only visibility; it is actionability. In plain English, the system helps users turn data into dosing decisions faster than periodic fingerstick checks. That matters because insulin treatment often depends on near-real-time data, especially around meals and corrections.

• 5-minute data updates for dosing decisions
• Use with insulin therapy workflows
• Clinical support for high- and low-glucose detection

DexCom's value proposition is strongest where monitoring frequency, wear duration, and access simplicity overlap. The numbers that define it are the 15-day wear period, 5-minute readings, 18+ OTC eligibility for non-insulin use, and 1-hour warm-up on Dexcom G7. These are the operational features that shape customer choice, channel strategy, and product differentiation.

DexCom, Inc. - Canvas Business Model: Customer Relationships

DexCom's customer relationships are built around self-service digital access, continuous app-based monitoring, and device-to-device integration. The relationship is designed to keep users engaged every day, because glucose data updates every 5 minutes and the newest G7 sensor is built for 10-day wear.

Relationship channel	Core customer need	Relevant number or feature	Why it matters
My Dexcom Account	Self-service account and order management	Digital portal access	Reduces friction for account tasks and keeps users inside the company's own digital system
Mobile app-based monitoring	Real-time glucose visibility	Glucose updates every 5 minutes	Creates a daily usage habit and makes the product hard to replace
Partner app integrations	Data sharing across devices and platforms	Compatible third-party apps and connected devices	Extends reach beyond the company's own app and supports ecosystem retention
G6 to G7 upgrade path	Lower switching friction for existing users	G7 sensor wear period: 10 days	Supports retention by making upgrades simple instead of forcing a new routine
Direct digital customer engagement	Education, onboarding, and support	App, portal, and digital communications	Improves adoption, reduces support friction, and keeps users linked to the brand

My Dexcom Account works as the company's self-service layer. It gives users a digital place to manage account-related activity without relying only on phone-based support. In customer relationship terms, this matters because a self-service portal lowers service costs per user and reduces delays in routine tasks. For academic analysis, you can treat it as a retention tool: once users create an account and keep using it for access and management, switching away becomes less convenient.

The portal also fits the company's recurring-revenue model because glucose monitoring is not a one-time purchase experience. It is a repeat-use relationship tied to sensors, software, and replacement cycles. The more a user depends on the portal for account control, the more the relationship shifts from a single product sale to an ongoing service connection.

Mobile app-based monitoring is the center of day-to-day customer engagement. Dexcom's CGM system sends glucose data every 5 minutes, which means the user is interacting with the system many times per day. That frequency is important because it builds routine. In business model terms, high-frequency usage increases product stickiness, which means users are less likely to stop using it once they rely on it for daily decisions.

• Real-time data delivery supports frequent app use.
• Alert-based monitoring increases trust in the system.
• Daily engagement creates repeated contact with the brand.
• Repeated contact improves the chances of renewal and upgrade.

Partner app integrations expand the relationship beyond the company's own app. This matters because customers do not live in a single digital system. Many want glucose data to connect with phones, watches, wellness tools, or health platforms. By linking into a broader ecosystem, the company makes its data easier to use and harder to abandon. That lowers churn risk because customers are not just buying a sensor; they are building a connected workflow around it.

For academic writing, partner integrations are a good example of ecosystem strategy. The company keeps the customer relationship alive through third-party compatibility rather than trying to own every touchpoint itself. That is a practical way to improve convenience without forcing users into a closed system.

Ongoing upgrade path from G6 to G7 is a retention mechanism. The G7 sensor uses a 10-day wear period, which helps create continuity for existing users moving from one generation to the next. When a company makes upgrading simple, it reduces the risk that customers will pause, compare alternatives, or abandon the category. In customer relationship terms, smoother upgrades protect lifetime value, which is the total revenue a customer can generate over time.

That upgrade path also matters because it turns product replacement into relationship renewal. Instead of losing the customer at the end of one device cycle, the company has a chance to keep them in the same app, the same account structure, and the same digital support flow. That is a strong academic example of how product development supports customer retention.

Direct digital customer engagement combines onboarding, education, alerts, and support inside a digital-first model. This is not just communication; it is relationship management. The company uses direct channels to explain setup, encourage use, and keep users active in the system. In a high-touch health technology category, that matters because user confidence affects adherence. If customers understand the product and trust the alerts, they are more likely to stay with it.

• Digital onboarding reduces early drop-off.
• Education improves correct use of the sensor and app.
• Ongoing alerts keep the user connected to the system.
• Support through digital channels can lower service friction.

Customer relationship element	Number or metric	Business effect
Glucose reading frequency	5 minutes	High engagement frequency
G7 wear period	10 days	Recurring replacement cycle and retention opportunity
Digital account structure	My Dexcom Account	Self-service relationship management
Integration model	Compatible partner apps and connected devices	Broader ecosystem use and lower switching risk

In Business Model Canvas terms, this customer relationship setup is a mix of self-service, automated service, and community or ecosystem-based support. The company keeps the customer close through frequent data updates, simple digital management, and upgrade continuity. That makes the relationship less dependent on one-time sales and more dependent on repeated digital engagement.

DexCom, Inc. - Canvas Business Model: Channels

DexCom, Inc. reaches users through mobile apps, a My Dexcom Account portal, pharmacy and reimbursement pathways, and partner distribution through the Oura app ecosystem and the Signos platform. The channel mix matters because DexCom sells a recurring, sensor-based product, so the route to the customer affects adoption, refill frequency, and access.

Channel	Function	Business impact	Real-life channel detail
Dexcom mobile apps	Display glucose data, alerts, and sharing functions	Supports user engagement and day-to-day product use	App-based viewing and sharing for continuous glucose monitoring
My Dexcom Account portal	Account setup, ordering support, and account management	Reduces friction in onboarding and fulfillment	Web-based customer account channel
Pharmacy and reimbursement channels	Prescription fulfillment and payer coverage	Drives scale through insurance access and retail pharmacy distribution	Prescription-based model with reimbursement dependence
Oura app ecosystem	Integrates glucose data into a third-party health app environment	Expands awareness and embedded use cases	Partner app distribution channel
Signos platform distribution	Uses DexCom data in a metabolic health platform	Reaches consumers through a guided digital health service	Partner-led consumer acquisition channel

Dexcom mobile apps are the most visible customer channel because they turn sensor output into daily glucose visibility. The channel is not just a display layer. It is part of the product experience itself, since continuous glucose monitoring depends on frequent app use for readings, alerts, and data review. That makes the app a retention tool as well as a delivery channel. For academic analysis, this matters because it shows that DexCom is not only selling hardware. It is selling a recurring digital-service experience around each sensor cycle.

The app channel also supports remote sharing, which is important for caregivers and clinicians. In continuous glucose monitoring, data sharing can influence adherence and clinical follow-up. That raises the value of the app beyond the user alone. The channel therefore supports both consumer use and clinical utility, which helps DexCom stay embedded in the user's daily routine.

• Channel role: daily data access
• Channel role: alert delivery
• Channel role: caregiver sharing
• Channel role: engagement during each sensor wear cycle

My Dexcom Account is the ownership and service channel. It helps users manage account details, product ordering, and support-related actions. In business model terms, this channel lowers friction between interest and repeat use. That is important in a prescription and refill model because every extra step can reduce conversion. The portal also supports repeat purchasing behavior, which matters in a product category with recurring replacement demand.

This channel is especially relevant where customers need a structured path from prescription to shipment. In a business where the sensor lifecycle is measured in days rather than years, a clean account and order process matters. A 10-day sensor wear period means the customer comes back to the company repeatedly, so the account channel affects continuity of demand.

• Channel role: account creation and management
• Channel role: ordering support
• Channel role: service and replenishment coordination
• Channel role: repeat-use continuity

Pharmacy and reimbursement channels are central to DexCom's scale. The company's model depends on prescription access and payer reimbursement because most users do not buy continuous glucose monitoring systems as ordinary retail items. The pharmacy channel shortens the time between prescription and product pickup or shipment, while reimbursement determines whether coverage lowers out-of-pocket cost.

For analysis, this channel is important because reimbursement drives adoption. If coverage expands, the addressable market grows faster. If coverage tightens, growth slows. That means the channel is not just a distribution route. It is a gatekeeper for revenue conversion. In practical terms, pharmacy access can be more efficient than durable medical equipment-style handling because it can simplify fulfillment and improve refill flow.

• Channel role: prescription fulfillment
• Channel role: payer access
• Channel role: lower consumer friction when coverage is available
• Channel role: recurring refill behavior

DexCom's channel economics are tied to recurring usage. A 10-day sensor cycle means a user may need 36 sensors in a 360-day period if use is continuous. That is why pharmacy and reimbursement access matter so much. The channel is built around repeated fulfillment rather than one-time device sale economics.

Oura app ecosystem functions as a partner distribution channel. DexCom's glucose data can be surfaced inside a third-party wellness environment, which gives the company reach beyond its own app users. This matters because partner channels can expose DexCom data to consumers who may not begin with a diabetes-focused workflow. That broadens discovery and can support interest from users tracking sleep, activity, and metabolic health in one place.

This channel is strategically useful because it places DexCom inside a wider consumer health app with an existing user base. In business model terms, that can reduce customer acquisition friction. It also positions DexCom as part of a broader digital health stack rather than a stand-alone medical device.

• Channel role: third-party app integration
• Channel role: consumer discovery outside DexCom-owned apps
• Channel role: broader metabolic health positioning

Signos platform distribution is another partner channel that embeds DexCom data in a guided consumer platform. This matters because a platform model can combine device data, coaching, and behavior support in one customer journey. For DexCom, the channel extends reach into users who enter through a metabolic health service instead of a direct sensor purchase.

That type of channel is important in academic analysis because it shows multi-sided distribution. DexCom is not only selling to patients and payers. It is also enabling partner platforms that package its data inside a consumer service. This can improve accessibility, but it also means DexCom partly depends on partner experience design for customer conversion and retention.

Channel	Customer entry point	Value delivered	Strategic risk
Dexcom mobile apps	Direct app download and use	Glucose readings, alerts, and sharing	Low engagement if alerts and usability are weak
My Dexcom Account	Web portal login and order management	Account support and replenishment	Order friction can reduce repeat conversion
Pharmacy and reimbursement	Prescription and coverage approval	Lower access barriers where covered	Payer policy changes can slow adoption
Oura app ecosystem	Partner app integration	Metabolic health visibility inside a broader wellness app	Dependence on partner app adoption and integration quality
Signos platform distribution	Partner platform onboarding	Guided consumer experience around DexCom data	Partner-led customer experience can shape conversion

The channel structure fits a recurring-use model. A sensor system with a 10-day wear period creates repeated touchpoints through apps, portals, refill pathways, and partners. That makes channels a major driver of revenue continuity, not just sales access. The more efficiently DexCom converts prescriptions into active users and repeat fills, the stronger the channel economics become.

DexCom, Inc. - Canvas Business Model: Customer Segments

DexCom, Inc. sells continuous glucose monitoring systems to people with diabetes, especially adults with type 2 diabetes and people who use insulin, and it is expanding into non-insulin users, metabolic health consumers, payers, and providers. The customer base is large because diabetes is widespread: the International Diabetes Federation estimated 537 million adults aged 20 to 79 were living with diabetes in 2021, and the number was projected to rise to 643 million by 2030 and 783 million by 2045.

Customer segment	Real-life scale	What the segment needs	Why it matters to DexCom, Inc.
People with diabetes	537 million adults worldwide in 2021	Real-time glucose data, alerts, trend tracking, and fewer fingersticks	Largest addressable clinical market for continuous glucose monitoring
Adults with type 2 diabetes	Largest diabetes subtype globally	Simple, low-friction monitoring that supports medication and diet decisions	Main growth pool beyond type 1 diabetes and insulin-dependent users
Non-insulin users	Large and underpenetrated segment	Behavior feedback, visibility into food and activity effects, easier adoption	Expands volume well beyond traditional intensive insulin therapy
Metabolic health consumers	Includes people without diabetes who track glucose for wellness and weight-related goals	Personalized metabolic feedback and habit change signals	Creates a consumer channel outside disease management
Payers and providers	Commercial insurers, public programs, health systems, physicians, and clinics	Evidence of outcomes, cost control, adherence, and workflow fit	Controls access, reimbursement, and prescribing volume

People with diabetes are the core customer group. This segment includes type 1 diabetes, type 2 diabetes, gestational diabetes in some care settings, and insulin-treated patients who need frequent glucose visibility. The business logic is simple: diabetes management depends on knowing glucose levels, trends, and hypoglycemia risk. Continuous glucose monitoring supports that need better than episodic testing because it gives data throughout the day and night. This segment matters because it is the clinical foundation of the company's business model and the strongest use case for payer reimbursement and physician recommendation.

Adults with type 2 diabetes are a major growth segment because they represent a much larger population than type 1 diabetes. Global diabetes prevalence of 537 million adults in 2021 means the type 2 pool is large enough to support broad adoption if pricing, reimbursement, and ease of use continue to improve. For this segment, the main customer need is not only glucose measurement but also simple decision support. People with type 2 diabetes often want to understand how meals, movement, and medication affect glucose without having to use complex tools. That makes this segment important for scale, recurring sensor sales, and long-term revenue growth.

Non-insulin users are strategically important because they widen the market beyond patients on intensive insulin therapy. This group includes adults with type 2 diabetes who manage their condition with oral drugs, GLP-1 therapies, diet, exercise, or a mix of treatments. They may not need the same level of glucose management every day as insulin users, but they still benefit from pattern recognition and behavior feedback. For DexCom, Inc., this segment matters because it can increase the installed base of users and lower dependence on a narrower subset of high-acuity patients. It also raises the importance of insurer coverage and clinician support, because adoption in this group often depends on whether the product is paid for and recommended in routine care.

• Large potential user base beyond insulin-treated patients
• Lower clinical intensity, but still meaningful need for glucose visibility
• High sensitivity to out-of-pocket cost and reimbursement rules
• Important for recurring sensor demand if adoption becomes standard in primary care

Metabolic health consumers are people using glucose data to support wellness, nutrition, exercise, or weight management goals rather than traditional diabetes treatment. This segment is smaller and more consumer-driven than the medical segments, but it is strategically useful because it broadens the company's brand reach and creates a new demand source outside payer-heavy channels. The customer need here is individualized feedback. Users want to see how food choices, sleep, and physical activity affect glucose in real time. That makes the segment valuable for direct-to-consumer education, app engagement, and future cross-sell into clinical use if a user later develops prediabetes or diabetes.

Payers and providers are not the end users of the sensor in the same way a patient is, but they are a separate customer segment because they control access and adoption. Payers include commercial insurers, government programs, and pharmacy benefit managers. Providers include endocrinologists, primary care physicians, diabetes educators, clinics, and health systems. Their main need is evidence that continuous glucose monitoring improves outcomes, reduces acute events, and fits clinical workflows. This segment matters because it influences reimbursement coverage, prescribing patterns, and patient retention. Without payer support and provider confidence, even a strong consumer product faces slower adoption.

Segment	Primary decision maker	Primary buying trigger	Commercial impact
People with diabetes	Patient, clinician, insurer	Need for glucose visibility and better control	Recurring sensor use
Adults with type 2 diabetes	Patient and physician	Medication management and easier self-care	Largest expansion pool
Non-insulin users	Patient, payer, physician	Coverage and lifestyle support	Category expansion
Metabolic health consumers	Consumer	Wellness, weight, and habit tracking	Direct-to-consumer growth
Payers and providers	Plan, health system, clinic	Outcomes, cost control, workflow fit	Access and reimbursement

The segment mix is important because it affects how DexCom, Inc. sells, prices, and scales. Clinical diabetes users create the core recurring revenue base. Type 2 and non-insulin users expand the addressable market. Metabolic health consumers add a consumer layer. Payers and providers determine how fast each segment can grow through coverage and prescribing behavior. In practice, this means the customer base is not one market but several markets with different purchase logic, reimbursement rules, and usage patterns.

• Clinical users: people with diabetes who need daily glucose management
• High-volume growth users: adults with type 2 diabetes
• Coverage-sensitive users: non-insulin users
• Consumer-led users: metabolic health consumers
• Access gatekeepers: payers and providers

For academic work, this customer segmentation shows that the business model depends on both medical necessity and reimbursement structure. The same product can serve a patient who needs clinical care, a consumer who wants wellness feedback, and a payer that wants lower long-term costs. That mix makes the segment design central to understanding demand, growth, and adoption risk.

DexCom, Inc. - Canvas Business Model: Cost Structure

2024 revenue was $4.03 billion. The cost structure was driven mainly by manufacturing, research and development, and sales and marketing, with additional pressure from logistics, regulatory work, and legal spending.

Gross profit was $2.49 billion. That implies a gross margin of 61.8% and shows that production and supply chain execution are central to cost control.

Cost structure item	Real-life number	Period
Revenue	$4.03 billion	2024
Gross profit	$2.49 billion	2024
Gross margin	61.8%	2024

Manufacturing and capacity expansion are the largest fixed-cost drivers in the model. DexCom has to fund sensor production, assembly, quality control, and plant expansion before the related revenue is collected. In a business with continuous device demand, capacity additions matter because underused facilities raise unit costs, while constrained capacity can limit growth and hurt service levels.

• High-volume production requires clean-room operations, test systems, and quality inspection.
• Capacity expansion adds depreciation, equipment, and labor costs before output is fully ramped.
• Manufacturing yield has a direct effect on cost of revenue because scrap and rework raise unit cost.

R&D and software development are structural costs, not optional spending. DexCom must keep funding sensor accuracy, connectivity, app performance, cloud infrastructure, and interoperability work. For a medical device company, R&D is also tied to product life cycle protection because product refreshes and software updates are needed to preserve clinical relevance.

• R&D spending supports new sensor generations, algorithms, and mobile software.
• Software costs include engineering, validation, cybersecurity, and maintenance.
• These costs matter because they support future revenue, but they also reduce near-term operating profit.

Logistics and freight matter because DexCom ships a physical product with recurring replacement demand. Freight costs rise when the company serves many geographies, when air transport is needed, or when inventory has to be repositioned quickly. In a subscription-like model with continuous sensor replenishment, shipping expense is not a one-time cost; it recurs with each customer cycle.

• Freight affects cost of sales when products move from plants to distribution points and customers.
• International shipping adds customs, handling, and inventory transfer costs.
• Delivery reliability matters because late shipments can disrupt patient use and increase support costs.

Regulatory and recall costs are part of operating in a medical device market. These costs include submissions, clinical documentation, quality systems, post-market surveillance, and corrective actions if product issues arise. They are important because every product change must stay within regulatory rules, and any field action can create direct expense plus reputational damage.

Regulatory and quality cost category	Financial effect
Regulatory submissions	Internal labor, testing, and documentation expense
Post-market surveillance	Monitoring, complaint handling, and data analysis cost
Recall or field action	Replacement, logistics, communication, and quality remediation cost

Legal and litigation expenses can be meaningful in a company with valuable intellectual property and a regulated product set. Legal spending covers patent defense, commercial disputes, employment matters, contract review, and compliance support. These costs affect operating margins because they do not directly create revenue, but they can protect market position and product rights.

• Patent disputes can be expensive because they require outside counsel and technical experts.
• Contract and compliance work rises as the company expands partnerships and geography.
• Litigation reserves, if recorded, can create volatility in quarterly earnings.

Cost bucket	Why it matters for the business model	Financial impact
Manufacturing and capacity expansion	Supports product supply and growth	Raises fixed costs and depreciation
R&D and software development	Protects product leadership and future sales	Reduces current operating profit
Logistics and freight	Moves product to patients and distributors	Raises cost of sales
Regulatory and recall costs	Keeps products approved and marketable	Can create sudden expense spikes
Legal and litigation expenses	Protects IP and limits compliance risk	Can pressure margins in disputed periods

DexCom, Inc. - Canvas Business Model: Revenue Streams

$3.62 billion in total revenue in 2023 came mainly from continuous glucose monitoring sensor sales and related consumables.

Revenue stream	Real-life disclosed numbers	What it means for revenue
G7 sensor sales	G7 launched in the U.S. in December 2022; DexCom reported total 2023 revenue of $3.62 billion	Primary growth engine as the newer CGM platform replaces older systems
G6 legacy sensor sales	G6 remained a marketed product alongside G7 in 2023 and 2024	Still contributes revenue from an installed base that had not fully migrated to G7
Stelo biosensor sales	Stelo received U.S. FDA clearance in March 2024	Opens a direct-to-consumer, over-the-counter revenue stream
Dexcom Flex sales	Dexcom introduced Dexcom Flex in 2024	Supports subscription-style or flexible access purchases for consumers
Reimbursed CGM device revenue	DexCom reported 2023 revenue growth of 24% year over year	Payer and pharmacy reimbursement remains the largest commercialization route for CGM adoption

G7 sensor sales are the clearest core revenue stream. DexCom's G7 platform is the company's newest mass-market CGM system, and its launch in the U.S. in December 2022 shifted sales toward the newer product set in 2023 and 2024. Because DexCom does not publicly break out revenue by G7 alone, the best hard figure available is companywide revenue, which reached $3.62 billion in 2023. That scale matters because the company's revenue model depends on recurring sensor replacement, not one-time device sales.

• Recurring sensor use drives repeat purchases.
• Each new user can generate multiple sensor purchases per year.
• G7 matters because it sits at the center of DexCom's replacement cycle.

G6 legacy sensor sales still matter because DexCom continued to sell G6 after G7 entered the market. That means revenue did not switch overnight from one product to another. The legacy stream helps keep revenue stable during migration, especially for users, payers, and clinicians that remain on older stocked systems. DexCom has not publicly disclosed separate G6 sales revenue, so you can only state that G6 remained part of the marketed portfolio in 2023 and 2024.

Stelo biosensor sales create a different revenue path because Stelo was cleared by the U.S. FDA in March 2024 for adults not using insulin. That matters strategically because it opens access to a consumer market outside traditional prescription-heavy CGM reimbursement. DexCom has not publicly disclosed Stelo revenue as a separate number in the available filings through mid-2024, so no product-specific sales amount should be stated without a later filing.

• FDA clearance date: March 2024
• Target users: adults not using insulin
• Revenue logic: direct consumer access instead of only reimbursed prescription channels

Dexcom Flex sales add a purchase structure that can lower friction for users who want access without a traditional full commitment at the point of sale. DexCom introduced Dexcom Flex in 2024. The company has not publicly disclosed separate Flex revenue in the available financial reporting through mid-2024, so the only factual statement you can make is that it represents a commercial access model layered on top of the CGM product base.

Reimbursed CGM device revenue remains the largest structural channel because CGM is a prescription-driven medical device business in many markets. DexCom's 2023 revenue was $3.62 billion, up 24% from the prior year. That growth rate shows that reimbursement-backed demand was still scaling strongly. In academic writing, this stream matters because it links revenue to payer coverage, pharmacy benefit access, and doctor adoption rather than only to consumer demand.

Metric	Value	Period
Total revenue	$3.62 billion	2023
Year-over-year revenue growth	24%	2023 vs. 2022
G7 U.S. launch	December 2022	Launch timing
Stelo FDA clearance	March 2024	Launch-enabling regulatory milestone
Dexcom Flex introduction	2024	Commercial model change

For a Business Model Canvas, these revenue streams show a company built on repeatable product consumption. The relevant number is not a one-time device sale; it is the recurring purchase cycle created by sensor replacement, payer reimbursement, and new consumer channels. That is why $3.62 billion in 2023 revenue is better understood as a recurring-use model than as a hardware-only model.